BRISTOL-MYERS SQUIBB CO (BRM.DE) Stock Price, Quote, News and Overview
FRA:BRM - Deutsche Boerse Ag - US1101221083 - Common Stock - Currency: EUR
BRM.DE Quote, Performance and Key Statistics
FRA:BRM (7/4/2025, 5:24:45 PM)
39.98
+0.02 (+0.06%)
The current stock price of BRM.DE is 39.98 EUR. In the past month the price decreased by -5.81%. In the past year, price increased by 9.55%.
BRM.DE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY.DE | ELI LILLY & CO | 56.85 | 629.30B | ||
| 1LLY.MI | ELI LILLY & CO | 56.66 | 627.21B | ||
| ZEG.DE | ASTRAZENECA PLC | 15.98 | 367.56B | ||
| JNJ.DE | JOHNSON & JOHNSON | 15.53 | 318.80B | ||
| 1JNJ.MI | JOHNSON & JOHNSON | 15.52 | 318.47B | ||
| NOV.DE | NOVO NORDISK A/S-B | 19.25 | 269.45B | ||
| RHO.DE | ROCHE HOLDING AG-BR | 14.63 | 237.92B | ||
| NOT.DE | NOVARTIS AG-REG | 14.7 | 204.42B | ||
| SAN.PA | SANOFI | 10.83 | 202.70B | ||
| SNW.DE | SANOFI | 10.72 | 200.66B | ||
| 1MRKX.MI | MERCK & CO. INC. | 10.61 | 176.02B | ||
| 6MK.DE | MERCK & CO. INC. | 10.42 | 173.01B |
Related stock screener links
About BRM.DE
Company Profile
Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. The company is headquartered in Princeton, New Jersey and currently employs 34,100 full-time employees. The company is engaged in the discovery, development and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its platforms comprise chemically synthesized or small molecule drugs, including protein degraders; drugs produced from biological processes, called biologics; ADCs, CAR-T cell therapies, and radiopharmaceutical therapeutics. Small molecule drugs are typically administered orally in the form of a tablet or capsule, although other drug delivery mechanisms are also used. Biologics are typically administered through injections or by intravenous infusion. CAR-T cell therapies are administered by intravenous infusion. Its growth portfolio includes Opdivo, Opdivo Qvantig, Orencia, Yervoy, Reblozyl, Opdualag, and others. Its legacy portfolio includes Eliquis, Revlimid, Pomalyst/Imnovid, Sprycel and Abraxane.
Company Info
BRISTOL-MYERS SQUIBB CO
Route 206 And Province Line Road
Princeton NEW JERSEY US
Employees: 34100
Phone: 16092524621
BRISTOL-MYERS SQUIBB CO / BRM.DE FAQ
What is the stock price of BRISTOL-MYERS SQUIBB CO today?
The current stock price of BRM.DE is 39.98 EUR. The price increased by 0.06% in the last trading session.
What is the ticker symbol for BRISTOL-MYERS SQUIBB CO stock?
The exchange symbol of BRISTOL-MYERS SQUIBB CO is BRM and it is listed on the Deutsche Boerse Ag exchange.
On which exchange is BRM.DE stock listed?
BRM.DE stock is listed on the Deutsche Boerse Ag exchange.
What is the price forecast or stock price prediction for BRISTOL-MYERS SQUIBB CO stock?
32 analysts have analysed BRM.DE and the average price target is 48.82 EUR. This implies a price increase of 22.11% is expected in the next year compared to the current price of 39.98. Check the BRISTOL-MYERS SQUIBB CO stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is BRISTOL-MYERS SQUIBB CO worth?
BRISTOL-MYERS SQUIBB CO (BRM.DE) has a market capitalization of 81.36B EUR. This makes BRM.DE a Large Cap stock.
How many employees does BRISTOL-MYERS SQUIBB CO have?
BRISTOL-MYERS SQUIBB CO (BRM.DE) currently has 34100 employees.
What are the support and resistance levels for BRISTOL-MYERS SQUIBB CO (BRM.DE) stock?
BRISTOL-MYERS SQUIBB CO (BRM.DE) has a resistance level at 40.24. Check the full technical report for a detailed analysis of BRM.DE support and resistance levels.
Is BRISTOL-MYERS SQUIBB CO (BRM.DE) expected to grow?
The Revenue of BRISTOL-MYERS SQUIBB CO (BRM.DE) is expected to decline by -3.38% in the next year. Check the estimates tab for more information on the BRM.DE EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy BRISTOL-MYERS SQUIBB CO (BRM.DE) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of BRM.DE, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of BRM.DE, evaluating the profitability, health, valuation and growth aspects
- BRISTOL-MYERS SQUIBB CO (BRM.DE) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- BRISTOL-MYERS SQUIBB CO (BRM.DE) Sales and EPS estimates to see what analysts future expectations are.
- BRISTOL-MYERS SQUIBB CO (BRM.DE) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- BRISTOL-MYERS SQUIBB CO (BRM.DE) Insider and Institutional Ownership to learn about the owners and their transactions.
- BRISTOL-MYERS SQUIBB CO (BRM.DE) Stock Chart to make your own analysis
- BRISTOL-MYERS SQUIBB CO (BRM.DE) Latest news and press-releases to stay up to date.
Does BRISTOL-MYERS SQUIBB CO (BRM.DE) stock pay dividends?
BRISTOL-MYERS SQUIBB CO (BRM.DE) has a dividend yield of 5.32%. The yearly dividend amount is currently 2.06. Check the full fundamental report for a detailed analysis of BRM.DE dividend history, reliability and sustainability.
When does BRISTOL-MYERS SQUIBB CO (BRM.DE) report earnings?
BRISTOL-MYERS SQUIBB CO (BRM.DE) will report earnings on 2025-07-31, before the market open.
What is the Price/Earnings (PE) ratio of BRISTOL-MYERS SQUIBB CO (BRM.DE)?
The PE ratio for BRISTOL-MYERS SQUIBB CO (BRM.DE) is 6.42. This is based on the reported non-GAAP earnings per share of 6.23 and the current share price of 39.98 EUR. Check the full fundamental report for a full analysis of the valuation metrics for BRM.DE.
BRM.DE Technical Analysis
BRM.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to BRM.DE. Both the profitability and the financial health of BRM.DE get a neutral evaluation. Nothing too spectacular is happening here.
BRM.DE Financial Highlights
Over the last trailing twelve months BRM.DE reported a non-GAAP Earnings per Share(EPS) of 6.23. The EPS increased by 599.05% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 11.38% | ||
| ROA | 5.86% | ||
| ROE | 31.16% | ||
| Debt/Equity | 2.67 |
BRM.DE Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 68% to BRM.DE. The Buy consensus is the average rating of analysts ratings from 32 analysts.
For the next year, analysts expect an EPS growth of 499.13% and a revenue growth -3.38% for BRM.DE